M M Sengayi1, D Kielkowski, M Egger, L Dreosti, J Bohlius. 1. National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. mazvita.sengayi@nhls.ac.za.
Abstract
BACKGROUND: When South Africa (SA) implemented its antiretroviral therapy (ART) programme in 2004, the model for treating HIV-positive Kaposi's sarcoma (KS) patients shifted from symptomatic palliation to potential cure. OBJECTIVE: To evaluate survival and changes over time in AIDS-KS patients treated at a tertiary academic hospital oncology unit (the Steve Biko Academic Hospital medical oncology unit) in Pretoria, SA, in the context of ART availability in SA. METHODS: We conducted a retrospective review of electronic and paper records of KS patients who accessed cancer care between May 2004 and September 2012. We used Kaplan-Meier survival functions to estimate 1- and 2-year survival, and Cox regression models to identify changes over time and prognostic factors. RESULTS: Our study included 357 AIDS-KS patients, almost all of whom were black Africans (n=353, 98.9%); 224 (62.7%) were men. The median age at cancer diagnosis was 37 (interquartile range (IQR) 30 - 43) years, and the median baseline CD4+ count was 242 (IQR 130 - 403) cells/µL. Most patients received ART (n=332, 93.0%) before or after KS diagnosis; 169 (47.3%) were treated with chemotherapy and 209 (58.6%) with radiation therapy. Mortality was 62.7% lower (adjusted hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.19 - 0.73) in the late (2009 - 2012) than in the early (2004 - 2008) ART period. Receiving chemotherapy (adjusted HR 0.3, 95% CI 0.15 - 0.61) and poor-risk AIDS Clinical Trials Group KS stage (adjusted HR 2.88, 95% CI 1.36 - 6.09) predicted mortality. CONCLUSIONS: Our results show that large national ART roll-out programmes can successfully reduce KS-related mortality at the individual patient level. If ART coverage is extended, KS-associated morbidity and mortality are likely to drop.
BACKGROUND: When South Africa (SA) implemented its antiretroviral therapy (ART) programme in 2004, the model for treating HIV-positive Kaposi's sarcoma (KS) patients shifted from symptomatic palliation to potential cure. OBJECTIVE: To evaluate survival and changes over time in AIDS-KSpatients treated at a tertiary academic hospital oncology unit (the Steve Biko Academic Hospital medical oncology unit) in Pretoria, SA, in the context of ART availability in SA. METHODS: We conducted a retrospective review of electronic and paper records of KS patients who accessed cancer care between May 2004 and September 2012. We used Kaplan-Meier survival functions to estimate 1- and 2-year survival, and Cox regression models to identify changes over time and prognostic factors. RESULTS: Our study included 357 AIDS-KSpatients, almost all of whom were black Africans (n=353, 98.9%); 224 (62.7%) were men. The median age at cancer diagnosis was 37 (interquartile range (IQR) 30 - 43) years, and the median baseline CD4+ count was 242 (IQR 130 - 403) cells/µL. Most patients received ART (n=332, 93.0%) before or after KS diagnosis; 169 (47.3%) were treated with chemotherapy and 209 (58.6%) with radiation therapy. Mortality was 62.7% lower (adjusted hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.19 - 0.73) in the late (2009 - 2012) than in the early (2004 - 2008) ART period. Receiving chemotherapy (adjusted HR 0.3, 95% CI 0.15 - 0.61) and poor-risk AIDS Clinical Trials Group KS stage (adjusted HR 2.88, 95% CI 1.36 - 6.09) predicted mortality. CONCLUSIONS: Our results show that large national ART roll-out programmes can successfully reduce KS-related mortality at the individual patient level. If ART coverage is extended, KS-associated morbidity and mortality are likely to drop.
Authors: Emmanuelle Boffi El Amari; Laurence Toutous-Trellu; Angèle Gayet-Ageron; Michele Baumann; Gieri Cathomas; Ingrid Steffen; Peter Erb; Nicolas J Mueller; Hansjakob Furrer; Matthias Cavassini; Pietro Vernazza; Hans H Hirsch; Enos Bernasconi; Bernard Hirschel Journal: AIDS Date: 2008-05-31 Impact factor: 4.177
Authors: Eric A Engels; Robert J Biggar; H Irene Hall; Helene Cross; Allison Crutchfield; Jack L Finch; Rebecca Grigg; Tara Hylton; Karen S Pawlish; Timothy S McNeel; James J Goedert Journal: Int J Cancer Date: 2008-07-01 Impact factor: 7.396
Authors: Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger Journal: Int J Cancer Date: 2014-05-02 Impact factor: 7.396
Authors: T Peter Kingham; Olusegun I Alatise; Verna Vanderpuye; Corey Casper; Francis A Abantanga; Thaim B Kamara; Olufunmilayo I Olopade; Muhammad Habeebu; Fatimah B Abdulkareem; Lynette Denny Journal: Lancet Oncol Date: 2013-04 Impact factor: 41.316
Authors: S Franceschi; M Lise; G M Clifford; M Rickenbach; F Levi; M Maspoli; C Bouchardy; S Dehler; G Jundt; S Ess; A Bordoni; I Konzelmann; H Frick; L Dal Maso; L Elzi; H Furrer; A Calmy; M Cavassini; B Ledergerber; O Keiser Journal: Br J Cancer Date: 2010-06-29 Impact factor: 7.640
Authors: Michalina A Montaño; Maganizo B Chagomerana; Margaret Borok; Matthew Painschab; Thomas S Uldrick; Rachel A Bender Ignacio Journal: Curr HIV/AIDS Rep Date: 2021-02-02 Impact factor: 5.071
Authors: Esther E Freeman; Aggrey Semeere; Devon E McMahon; Helen Byakwaga; Miriam Laker-Oketta; Susan Regan; Megan Wenger; Charles Kasozi; Matthew Ssemakadde; Mwebesa Bwana; Michael Kanyesigye; Philippa Kadama-Makanga; Elyne Rotich; Job Kisuya; Kara Wools-Kaloustian; Ingrid V Bassett; Naftali Busakhala; Jeffrey Martin Journal: J Acquir Immune Defic Syndr Date: 2021-08-15 Impact factor: 3.771
Authors: Naftali Busakhala; Gabriel Kigen; Paul Waako; R Matthew Strother; Fredrick Chite; Patrick Loehrer Journal: Infect Agent Cancer Date: 2019-09-10 Impact factor: 2.965
Authors: Katherine R Sabourin; Margaret Borok; Samantha Mawhinney; Maxwell Matimba; Francis Jaji; Suzanne Fiorillo; Dickson D Chifamba; Claudios Muserere; Busisiwe Mashiri; Chenjerai Bhodheni; Patricia Gambiza; Rachael Mandidewa; Mercia Mutimuri; Ivy Gudza; Matthew Mulvahill; Camille M Moore; Jean S Kutner; Eric A F Simões; Thomas B Campbell Journal: J Int AIDS Soc Date: 2022-08 Impact factor: 6.707
Authors: Vini Fardhdiani; Lucas Molfino; Ana Gabriela Zamudio; Rolanda Manuel; Gilda Luciano; Iza Ciglenecki; Barbara Rusch; Laurence Toutous Trellu; Matthew E Coldiron Journal: Infect Agent Cancer Date: 2018-01-19 Impact factor: 2.965